Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:
NCT00840931
First received: February 4, 2009
Last updated: July 10, 2014
Last verified: July 2014

February 4, 2009
July 10, 2014
February 2009
February 2015   (final data collection date for primary outcome measure)
Maximum Tolerated Dose (MTD) [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
Determination of MTD of GM.CD40L bystander vaccine with lenalidomide in high-risk MDS patients.
Determination of MTD of GM.CD40L bystander vaccine with lenalidomide in high-risk MDS patients. [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00840931 on ClinicalTrials.gov Archive Site
  • Number of Participants with Toxicities [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Determination of toxicities associated with combination of GM.CD40L bystander vaccine with lenalidomide in high-risk MDS patients.
  • Number of Participants with Augmentation of Specific T Cell Immunological Functions [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Augmentation of specific T cell immunological functions; T cell proliferation and Interferon-γ production, delayed type hypersensitivity (DTH) sensitivity by lenalidomide.
  • Number of Participants with Reduction of Bone Marrow Myeloblast [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Reduction of bone marrow myeloblast from baseline to post treatment with lenalidomide and GM.CD40L bystander vaccine.
  • Number of Participants with Improvement of Hemoglobin and/or red blood cell (RBC) Transfusion Independence [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Improvement of hemoglobin and/or RBC transfusion independence after combined immunotherapy treatment.
  • Number of Participants with Resolution of Karyotypic Changes [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Resolution of karyotypic changes after combined treatment.
  • Number of Participants with Augmentation of Other T Cell Parameters [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Augmentation of other T cell parameters after the combined treatment.
  • Duration of Response [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Determination of response duration evaluated by Wilms Tumor 1 (WT1) expression and clinical outcomes. Clinical response will be assessed using International Working Group (IWG) criteria.
  • Determination of toxicities associated with combination of GM.CD40L bystander vaccine with lenalidomide in high-risk MDS patients. [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  • Augmentation of specific T cell immunological functions (T cell proliferation and Interferon-γ production, DTH sensitivity) by lenalidomide. [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  • Reduction of bone marrow myeloblast from baseline to post treatment with lenalidomide and GM.CD40L bystander vaccine. [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  • Improvement of hemoglobin and/or RBC transfusion independence after combined immunotherapy treatment. [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  • Resolution of karyotypic changes after combined treatment. [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  • Augmentation of other T cell parameters after the combined treatment. [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  • Determination of response duration evaluated by WT1 expression and clinical outcomes. Clinical response will be assessed using International Working Group (IWG) criteria. [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)
A Phase I Pilot Study of Immunotherapy Using Lenalidomide Plus "Bystander" Vaccine in Patients With High-Risk Myelodysplastic Syndrome (MDS)

The purpose of this study is to find out the maximum tolerated dose (MTD) of the combined therapy of lenalidomide (Revlimid®) and Granulocyte/macrophage colony stimulating factor and CD40 Ligand expressed in the K562 cell line (GM.CD40L) bystander vaccine. This research is also being done to see how well the combination of these drugs works to fight myelodysplastic syndrome (MDS).

Fixed dose of lenalidomide at 10 mg/day, Days 1- 21 of 28 days of treatment cycle, and 4 dose escalations of GM.CD40L vaccine: 10 X 10^6 GM.CDL cells per vaccination; 30 X 10^6 GM.CDL cells per vaccination; 60 X 10^6 GM.CDL cells per vaccination; 120 X 10^6 GM.CDL cells per vaccination; Vaccination at 2-week intervals, on days 8 and 22, for a total of four 28-day cycles.

Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Leukemia
  • Drug: lenalidomide
    Patients will take 10 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Patients will receive 4 treatment cycles with 28 days in each cycle.
    Other Name: Revlimid®
  • Biological: bystander vaccine
    In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
    Other Name: GM.CD40L
Experimental: Immunotherapy
Participants will take two 5 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Participants will receive 4 treatment cycles with 28 days in each cycle. Those participants showing a clinical response after 4 cycles of treatment may continue to receive lenalidomide as a single agent for additional cycles at the treating Physicians discretion. During each 28 day cycle participants will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
Interventions:
  • Drug: lenalidomide
  • Biological: bystander vaccine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
22
February 2015
February 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must understand and voluntarily sign an informed consent form
  • Age ≥18 years at the time of signing the informed consent form
  • Able to comply with the study visit schedule and assessments required by the protocol
  • Documented diagnosis of MDS with subtypes of Refractory Anemia with Excess Blast 1 (RAEB-1) (myeloblast ≥5-9%) or Refractory Anemia with Excess Blast 2 (RAEB-2) (myeloblast ≥10-19%) or intermediate 2, Acute myelogenous leukemia with bone marrow myeloblast >30% and high risk defined by International Prognostic Scoring System (IPSS) scores or refractory anemia with excess blast in transformation (RAEB-t) (myeloblast ≥ 20-30%) as per French-American-British Classification System (FAB) criteria. Any single or combination of cytogenetic abnormalities is allowed.
  • Study treatment can be offered as first line treatment as long as the available food and Drug Administration (FDA) approved treatment options are explained by the treating physician and the participant declines such options.
  • Study treatment can be offered to patients who have failed, cannot tolerate or do not wish to continue other therapeutic agents for MDS.
  • Prior chemotherapy is allowed but should be off chemotherapy of any kind for at last 4 weeks prior to initiation of study therapy.
  • Must be able to provide adequate bone marrow (BM) aspirate and biopsy specimens for histopathological evaluation, cytogenetic analysis and tissue banking during the screening procedure.
  • Platelet count must be > 20,000/ µl without platelet transfusion.
  • Absolute neutrophil count (ANC) must be >500/ µl without myeloid growth factor support.
  • Should not be receiving erythropoietin and/or myeloid growth factor for at least 14 days prior to initiation of study therapy.
  • Should not have current diagnosis or prior history of any autoimmune or immune deficiency disorders including human immunodeficiency virus positive/acquired immunodeficiency syndrome (HIV+/AIDS).
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
  • Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
  • Both male and female and members of all races and ethnic groups are eligible for this study.

Exclusion Criteria:

  • Prior therapy with lenalidomide.
  • Proliferative chronic myelomonocytic leukemia (CMML with WBC≥12,000/µL in peripheral blood), confirmed by bone marrow biopsy.
  • Acute myelogenous leukemia with bone marrow myeloblast ≥30%
  • MDS secondary to treatment with radiotherapy, chemotherapy, and/or immunotherapy for malignant or autoimmune diseases are excluded.
  • Any of the following laboratory abnormalities:

    • Serum creatinine > 1.5 x upper limit of normal (ULN)
    • Serum aspartic transaminase (AST) or alanine transaminase (ALT) >2.0 x ULN
    • Serum total bilirubin > 2.0 mg/dL (34 µmol/L)
  • Prior ≥ grade-2 national Cancer Institute Common Toxicity Criteria (NCI CTC) allergic reaction to thalidomide.
  • Prior desquamating (blistering) rash while taking thalidomide.
  • Prior allergic reaction to vaccination of any sort.
  • Participants with ≥ grade-2 neuropathy.
  • Clinically significant anemia due to factors such as iron, B12 or folate deficiencies, autoimmune or hereditary hemolysis or gastrointestinal bleeding.
  • Use of cytotoxic chemotherapeutic agents, growth factors, or experimental agents (agents that are not commercially available) for the treatment of MDS within 28 days of the start of drug treatment.
  • Prior history of malignancy other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix) unless the participant has been free of disease for ≥3 years.
  • Any serious medical condition or psychiatric illness that will prevent the participant from signing the informed consent form or will place the participant at unacceptable risk if he/she participates in the study.
  • Pregnant or nursing females.
  • Use of corticosteroids greater than the equivalent of prednisone 10mg daily within 4 weeks of the first vaccination, and on-going need for corticosteroids greater than the equivalent of prednisone 10 mg daily
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00840931
MCC-14998, 105861, RV-MDS-PI-202, BB-IND 13478, 0803-907
Yes
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation
Principal Investigator: Javier Pinilla, M.D., Ph.D. H. Lee Moffitt Cancer & Research Institute
H. Lee Moffitt Cancer Center and Research Institute
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP